Virus levels after stem cell transplant for CMV prevention
Part of Blood & lymphatic, Infections clinical trials.
This study checks whether certain virus levels in your blood after a stem cell transplant can help predict or prevent CMV infection. It aims to improve how doctors monitor and protect patients from this virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have had a stem cell transplant (also called a bone marrow transplant).
- You or your stem cell donor must have had CMV (a common virus) in the past.
- You must be taking letermovir, a medicine to prevent CMV infection, for about 3 to 6 months after your transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This study tests whether a blood test can help doctors decide how long to continue letermovir (a medicine that prevents a common viral infection called CMV) after a stem cell transplant. The goal is to see if a shorter course is safe and effective for some patients.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.